keyword
https://read.qxmd.com/read/38596319/ketamine-based-sedation-use-in-mechanically-ventilated-critically-ill-patients-with-covid-19-a-multicenter-cohort-study
#1
JOURNAL ARTICLE
Ohoud Aljuhani, Khalid Al Sulaiman, Ghazwa B Korayem, Ali F Altebainawi, Abdulrahman Alshaya, Majed Nahari, Khuzama Alsamnan, Munirah A Alkathiri, Bodoor S Al-Dosari, Abeer A Alenazi, Samiah Alsohimi, Lina I Alnajjar, Mashael Alfaifi, Nora AlQussair, Reem M Alanazi, Munirah F Alhmoud, Nadin L Alanazi, Hadeel Alkofide, Aljawharah M Alenezi, Ramesh Vishwakarma
BACKGROUNDS: Ketamine possesses analgesia, anti-inflammation, anticonvulsant, and neuroprotection properties. However, the evidence that supports its use in mechanically ventilated critically ill patients with COVID-19 is insufficient. The study's goal was to assess ketamine's effectiveness and safety in critically ill, mechanically ventilated (MV) patients with COVID-19. METHODS: Adult critically ill patients with COVID-19 were included in a multicenter retrospective-prospective cohort study...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38559401/former-smoking-but-not-active-smoking-is-associated-with-delirium-in-postoperative-icu-patients-a-matched-case-control-study
#2
JOURNAL ARTICLE
Maria Angeliki Komninou, Simon Egli, Aurelio Rossi, Jutta Ernst, Michael Krauthammer, Reto A Schuepbach, Marcos Delgado, Jan Bartussek
OBJECTIVE: To examine the relationship between current and former smoking and the occurrence of delirium in surgical Intensive Care Unit (ICU) patients. METHODS: We conducted a single center, case-control study involving 244 delirious and 251 non-delirious patients that were admitted to our ICU between 2018 and 2022. Using propensity score analysis, we obtained 115 pairs of delirious and non-delirious patients matched for age and Simplified Acute Physiology Score II (SAPS II)...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38405040/nmda-receptor-modulation-by-esculetin-investigating-behavioral-biochemical-and-neurochemical-effects-in-schizophrenic-mice-model
#3
JOURNAL ARTICLE
Iqra Khalid, Uzma Saleem, Bashir Ahmad, Mohammed F Hawwal, Ramzi A Mothana
Schizophrenia, a global mental health disorder affecting approximately 1 % of the population, is characterized by neurotransmitter dysregulation, particularly dopamine, serotonin, and glutamate. Current antipsychotic therapies, despite their efficacy, are accompanied by adverse effects, which has motivated researchers to investigate more secure substitutes. This study examines the potential antipsychotic effects of esculetin, a natural coumarin derivative recognized for its wide-ranging pharmacological activities (anti-inflammatory, antioxidant, anti-pathogenic, anticancer, and neuroprotective), in animal model of schizophrenia induced by ketamine...
April 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://read.qxmd.com/read/38371525/effects-of-nostoc-commune-extract-on-the-cerebral-oxidative-and-neuroinflammatory-status-in-a-mice-model-of-schizophrenia
#4
JOURNAL ARTICLE
Parisa Jahani Bahnamiri, Akbar Hajizadeh Moghaddam, Mojtaba Ranjbar, Ehsan Nazifi
Cyanobacterium Nostoc commune has long been used to alleviate various diseases. This research examines the effects of Nostoc commune extract (NCE) against behavioral disorders, cerebral oxidative stress, and inflammatory damage in the ketamine-induced schizophrenia model. Oral NCE administration (70 and 150 mg/kg/d) is performed after intraperitoneal ketamine injection (20 mg/kg) for 14 consecutive days. The forced swimming and open field tests are used to assess schizophrenia-like behaviors. After the behavioral test, dopamine (DA) level, oxidative stress markers, as well as the interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) expression are measured in the cerebral cortex...
March 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/38352457/transient-peripheral-blood-transcriptomic-response-to-ketamine-treatment-in-children-with-adnp-syndrome
#5
Ariela S Buxbaum Grice, Laura Sloofman, Tess Levy, Hannah Walker, Gauri Ganesh, Miguel Rodriguez de Los Santos, Pardis Armini, Joseph D Buxbaum, Alexander Kolevzon, Ana Kostic, Michael S Breen
Activity-dependent neuroprotective protein (ADNP) syndrome is a rare neurodevelopmental disorder resulting in intellectual disability, developmental delay and autism spectrum disorder (ASD) and is due to mutations in the ADNP gene. Ketamine treatment has emerged as a promising therapeutic option for ADNP syndrome, showing safety and apparent behavioral improvements in a first open label study. However, the molecular perturbations induced by ketamine remain poorly understood. Here, we investigated the longitudinal effect of ketamine on the blood transcriptome of 10 individuals with ADNP syndrome...
January 31, 2024: medRxiv
https://read.qxmd.com/read/38318342/neuroprotective-effects-of-alpha-pinene-against-behavioral-deficits-in-ketamine-induced-mice-model-of-schizophrenia-focusing-on-oxidative-stress-status
#6
JOURNAL ARTICLE
Akbar Hajizadeh Moghaddam, Fatemeh Malekzadeh Estalkhi, Sedigheh Khanjani Jelodar, Tabarek Ahmed Hasan, Soroush Farhadi-Pahnedari, Mohammad Karimian
Schizophrenia (SCZ) is a profound neurological disorder that affects approximately 1% of the global population. Alpha-pinene (α-pinene) is a natural and active monoterpene found in coniferous tree oil, primarily pine, with diverse pharmacological characteristics, including antioxidative, anxiolytic, and antidepressant properties. This research study delves into the neuroprotective effects of α-pinene on oxidative stress, memory deficits, and depressive and anxiety-like behaviors in a ketamine-induced mice model of SCZ using male mice...
June 2024: IBRO neuroscience reports
https://read.qxmd.com/read/38295061/esketamine-less-drowsiness-more-analgesia
#7
JOURNAL ARTICLE
Georges Mion, Sabine Himmelseher
Racemic ketamine is a 1:1 mixture of 2 enantiomers that turn light in opposite direction: Dextrorotatory esketamine is approximately 4 times more affine for the N-methyl-D-aspartate (NMDA) receptor than levorotatory arketamine, which may explain why esketamine is about twice as potent as an analgesic and anesthetic as the racemate. Esketamine has attracted renewed interest in view of the opioid crisis, racemic ketamine's abuse, and esketamine's approval for expanded use. We evaluated the anesthesia literature concerning mental, cardiovascular, cerebral, and antinociceptive effects of esketamine published in English between 1980 and 2022...
January 31, 2024: Anesthesia and Analgesia
https://read.qxmd.com/read/38099265/evaluating-the-effects-of-s-ketamine-on-postoperative-delirium-in-elderly-patients-following-total-hip-or-knee-arthroplasty-under-intraspinal-anesthesia-a-single-center-randomized-double-blind-placebo-controlled-pragmatic-study-protocol
#8
JOURNAL ARTICLE
Youzhuang Zhu, Wei Feng, Qinghan Kong, Fang Sheng, Zhichao Li, Weilong Xu, Qun Li, Yan Han, Xiuyun Wu, Changxin Jia, Jie Guo, Yang Zhao
INTRODUCTION: Postoperative delirium (POD) is an acute, transient brain disorder associated with decreased postoperative quality of life, dementia, neurocognitive changes, and mortality. A small number of trials have explored the role of S-ketamine in the treatment of POD due to its neuroprotective effects. Surprisingly, these trials have failed to yield supportive results. However, heterogeneity in delirium assessment methodologies, sample sizes, and outcome settings as well as deficiencies in S-ketamine use methods make the evidence provided by these studies less persuasive...
2023: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/38091390/memantine-inhibits-cortical-spreading-depolarization-and-improves-neurovascular-function-following-repetitive-traumatic-brain-injury
#9
JOURNAL ARTICLE
Mark A MacLean, Jamil H Muradov, Ryan Greene, Gerben Van Hameren, David B Clarke, Jens P Dreier, David O Okonkwo, Alon Friedman
Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively...
December 15, 2023: Science Advances
https://read.qxmd.com/read/38084605/curcumin-zno-conjugated-nanoparticles-confer-neuroprotection-against-ketamine-induced-neurotoxicity
#10
JOURNAL ARTICLE
Fatemeh Mobinhosseini, Mahsa Salehirad, A Wallace Hayes, Majid Motaghinejad, Malak Hekmati, Sepideh Safari, Mina Gholami
BACKGROUND: Nanotechnology and its application to manipulate herbal compounds to design new neuroprotective agents to manage neurotoxicity has recently increased. Cur-ZnO conjugated nanoparticles were synthesized and used in an experimental model of ketamine-induced neurotoxicity. METHODS: Cur-ZnO conjugated nanoparticles were chemically characterized, and the average crystalline size was determined. Forty-nine adult mice were divided into seven groups of seven animals each...
December 12, 2023: Journal of Biochemical and Molecular Toxicology
https://read.qxmd.com/read/38070725/effect-of-esketamine-pretreatment-on-acute-sepsis-associated-encephalopathy
#11
JOURNAL ARTICLE
Cong-Mei Wang, Yan Zhang, Yu-Shen Yang, Shu Lin, He-Fan He
PURPOSE: Esketamine, the S(+) enantiomer of ketamine, exhibits good anesthetic efficacy and controllability; however, its potential clinical applications, particularly in sepsis-associated encephalopathy (SAE), remain underexplored. SAE involves the development of diffuse brain dysfunction after sepsis, leading to markedly increased sepsis-related disability and mortality. In this study, we investigated the effects of esketamine pretreatment on acute SAE. METHODS: Mice were randomly divided into four groups: control (C, n = 22), acute SAE (L, n = 22), esketamine pretreatment + acute SAE (EL, n = 22), and nuclear factor erythroid 2-related factor 2 (Nrf2) inhibitor (ML385) + esketamine pretreatment + acute SAE (N + EL, n = 22)...
December 7, 2023: Experimental Neurology
https://read.qxmd.com/read/38064277/neuroprotective-effect-of-ketamine-and-sevoflurane-against-tnf-%C3%AE-induced-cognitive-impairment
#12
JOURNAL ARTICLE
Yuanshui Wu, Meilan Zhang, Hongyan Ke, Juanjuan Xu, Huanhuan Li, Xiaohong Ni
In the present study, neuroprotective effect of sevoflurane in combination with ketamine was investigated on TNF-α induced necroptosis of neurons and cognitive impairment in the rat model. The results demonstrated that exposure to TNF-α/z-VAD led to a significant decrease in viability of HT-22 neuronal cells. However, incubation of HT-22 cells with ketamine plus sevoflurane inhibited decrease in viability induced by TNF-α/z-VAD exposure. The increase in production of ROS by TNF-α/z-VAD exposure in HT-22 cells was effectively suppressed on pre-treatment with ketamine plus sevoflurane...
December 8, 2023: Environmental Toxicology
https://read.qxmd.com/read/37985012/anaesthesia-related-cognitive-dysfunction-following-cardiothoracic-surgery-in-late-middle-age-and-younger-adults-a-scoping-review
#13
REVIEW
Hesam Aldin Varpaei, Lorraine B Robbins, Jiying Ling, Rebecca H Lehto, Catherine M Bender
AIM: This review aimed to evaluate factors associated with anaesthesia-related postoperative cognitive dysfunction (POCD) among adults younger than 65 years who underwent cardiothoracic surgeries. STUDY DESIGN: A systematic keyword search, following the scoping review framework, was performed in the PubMed and CINAHL databases. Original English-language studies that included adults younger than 65 years and addressed cognitive function after surgery along with anaesthesia management were included...
November 20, 2023: Nursing in Critical Care
https://read.qxmd.com/read/37977808/-ketamine-a-new-antidepressant-drug-with-anti-inflammatory-properties
#14
JOURNAL ARTICLE
Marta Jóźwiak-Bębenista, Paulina Sokołowska, Anna Wiktorowska-Owczarek, Edward Kowalczyk, Monika Sienkiewcz
Ketamine is a new, potent and rapid-acting antidepressant approved for therapy of treatment-resistant depression, which has a different mechanism of action than currently-available antidepressant therapies. It owes its uniquely potent antidepressant properties to a complex mechanism of action, which currently remains unclear. However, it is thought that it acts by modulating the functioning of the glutamatergic system, which plays an important role in the process of neuroplasticity associated with depression...
November 17, 2023: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/37778171/dexmedetomidine-compared-to-low-dose-ketamine-better-protected-not-only-the-brain-but-also-the-lungs-in-acute-ischemic-stroke
#15
JOURNAL ARTICLE
Luciana B B Heil, Cassia L Braga, Raquel F Magalhães, Mariana A Antunes, Fernanda F Cruz, Cynthia S Samary, Denise Battaglini, Chiara Robba, Paolo Pelosi, Pedro L Silva, Patricia R M Rocco
BACKGROUND: Dexmedetomidine (DEX) and low-dose ketamine (KET) present neuroprotective effects in acute ischemic stroke (AIS); however, to date, no studies have evaluated which has better protective effects not only on the brain but also lungs in AIS. METHODS: AIS-induced Wistar rats (390 ± 30 g) were randomized after 24-h, receiving dexmedetomidine (STROKE-DEX, n = 10) or low-dose S(+)-ketamine (STROKE-KET, n = 10). After 1-h protective ventilation, perilesional brain tissue and lungs were removed for histologic and molecular biology analysis...
September 29, 2023: International Immunopharmacology
https://read.qxmd.com/read/37759476/nap-davunetide-the-neuroprotective-adnp-drug-candidate-penetrates-cell-nuclei-explaining-pleiotropic-mechanisms
#16
JOURNAL ARTICLE
Maram Ganaiem, Nina D Gildor, Shula Shazman, Gidon Karmon, Yanina Ivashko-Pachima, Illana Gozes
(1) Background: Recently, we showed aberrant nuclear/cytoplasmic boundaries/activity-dependent neuroprotective protein (ADNP) distribution in ADNP-mutated cells. This malformation was corrected upon neuronal differentiation by the ADNP-derived fragment drug candidate NAP (davunetide). Here, we investigated the mechanism of NAP nuclear protection. (2) Methods: CRISPR/Cas9 DNA-editing established N1E-115 neuroblastoma cell lines that express two different green fluorescent proteins (GFPs)-labeled mutated ADNP variants (p...
September 11, 2023: Cells
https://read.qxmd.com/read/37588789/circulating-oxylipin-and-bile-acid-profiles-of-dexmedetomidine-propofol-sevoflurane-and-s-ketamine-a-randomised-controlled-trial-using-tandem-mass-spectrometry
#17
JOURNAL ARTICLE
Aleksi Nummela, Lauri Laaksonen, Annalotta Scheinin, Kaike Kaisti, Tero Vahlberg, Mikko Neuvonen, Katja Valli, Antti Revonsuo, Markus Perola, Mikko Niemi, Harry Scheinin, Timo Laitio
BACKGROUND: This exploratory study aimed to investigate whether dexmedetomidine, propofol, sevoflurane, and S-ketamine affect oxylipins and bile acids, which are functionally diverse molecules with possible connections to cellular bioenergetics, immune modulation, and organ protection. METHODS: In this randomised, open-label, controlled, parallel group, Phase IV clinical drug trial, healthy male subjects ( n =160) received equipotent doses (EC50 for verbal command) of dexmedetomidine (1...
December 2022: BJA Open
https://read.qxmd.com/read/37586559/resveratrol-plays-neuroprotective-role-on-ketamine-induced-schizophrenia-like-behaviors-and-oxidative-damage-in-mice
#18
JOURNAL ARTICLE
Alireza Farkhakfar, Shahin Hassanpour, Morteza Zendehdel
This study aimed to determine effects of the resveratrol on ketamine-induced schizophrenia-like behaviors and oxidative damage in mice. Twenty-four male mice were allocated into four experimental groups as control, ketamine (20mg/kg), resveratrol (80mg/kg) and co-administration of the ketamine (20mg/kg) + resveratrol (80mg/kg). Mice were received resveratrol for 30 days and ketamine was used for an animal model of schizophrenia and was injected from days 16 to 30 of the study. After the drug administration was finished, schizophrenia-like behaviors were evaluated using object recognition test, tail suspension test, forced swimming test and open field test and brain malondialdehyde, glutathione peroxidase, superoxide dismutase and catalase levels were determined...
August 14, 2023: Neuroscience Letters
https://read.qxmd.com/read/37521706/the-cellular-mechanisms-associated-with-the-anesthetic-and-neuroprotective-properties-of-xenon-a-systematic-review-of-the-preclinical-literature
#19
Steven McGuigan, Daniel J Marie, Liam J O'Bryan, Francisco J Flores, Lisbeth Evered, Brendan Silbert, David A Scott
INTRODUCTION: Xenon exhibits significant neuroprotection against a wide range of neurological insults in animal models. However, clinical evidence that xenon improves outcomes in human studies of neurological injury remains elusive. Previous reviews of xenon's method of action have not been performed in a systematic manner. The aim of this review is to provide a comprehensive summary of the evidence underlying the cellular interactions responsible for two phenomena associated with xenon administration: anesthesia and neuroprotection...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/37491939/low-dose-ketamine-improves-animals-locomotor-activity-and-decreases-brain-oxidative-stress-and-inflammation-in-ammonia-induced-neurotoxicity
#20
JOURNAL ARTICLE
Mohammad Mehdi Ommati, Ali Mobasheri, Hossein Niknahad, Mohammad Rezaei, Sepideh Alidaee, Abdollah Arjmand, Sahra Mazloomi, Narges Abdoli, Issa Sadeghian, Samira Sabouri, Mohsen Saeed, Khadijeh Mousavi, Asma Najibi, Reza Heidari
Ammonium ion (NH4 + ) is the major suspected molecule responsible for neurological complications of hepatic encephalopathy (HE). No specific pharmacological action for NH4 + -induced brain injury exists so far. Excitotoxicity is a well-known phenomenon in the brain of hyperammonemic cases. The hyperactivation of the N-Methyl- d-aspartate (NMDA) receptors by agents such as glutamate, an NH4 + metabolite, could cause excitotoxicity. Excitotoxicity is connected with events such as oxidative stress and neuroinflammation...
July 26, 2023: Journal of Biochemical and Molecular Toxicology
keyword
keyword
90572
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.